# A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects

> **NCT07267130** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.** · enrollment: 57 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** TQC3302 inhalation spray
- **DRUG:** TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation
- **DRUG:** Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray
- **DRUG:** Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray
- **DRUG:** TQC3302 inhalation spray

## Key facts

- **NCT ID:** NCT07267130
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267130, "A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07267130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*